Blogs
CATEGORIES [ ASCO ]

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

BY DEBU TRIPATHY | JUNE 5, 2013

Debu Tripathy blog image
Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

RELATED POSTS

COMMENTS

There are no comments for this entry.

ADD A COMMENT

Your comment will appear once approved by CURE staff:
* Required fields